| Biomarker ID | 876 |
| PMID | 22355332 |
| Year | 2012 |
| Biomarker | Beta 2-Glycoprotein 1 + Somatomedin- B |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Downregulated [Beta 2-Glycoprotien 1 (1.1 fold) + Somatomedin- B (1.2 fold)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Non Progressing Vs Progressing Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | Samples were collected from 4 groups with 5 samples each:benign prostatic hyperplasia (BPH); ii) localised cancer with no evidence of progression, (non-progressing) (iii) localised cancer with evidence of biochemical progression, (progressin), and (iv) bone metastasis at presentation (metastatic). |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p ≤0.01 |
| Method Used | 4-plex iTRAQ |
| Clinical | No |
| Remarks | represents biomarkers assessed individualy, + represents biomarkers assessed as a pair or panel |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | APOH, VTN |